REVOLADE 25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

USDailyMed:Eltrombopag olamine AU:B3 B02BX05(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-only 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid 496775-61-2Nas olamine:496775-62-3 9846180as olamine:135449331 DB06210Yas olamine:DBSALT000063 21106301Yas olamine:28475107 S56D65XJ9Gas olamine:4U07F515LG D03978 CHEBI:85010 ChEMBL461101Nas olamine:ChEMBL3989691 DTXSID5057753 Interactive image CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,26,30H,1-3H3,(H,32,33)/b27-22-YKey:XDXWLKQMMKQXPV-QYQHSDTDSA-NY Eltrombopag, sold under the brand namePromactaamong others, is a medication used to treatthrombocytopenia(abnormally lowplateletcounts) and severe aplastic anemia.Eltrombopag is sold under the brand nameRevoladeoutside the US and is marketed byNovartis.It is athrombopoietin receptor agonist.It is takenby mouth. Eltrombopag was discovered as a result of research collaboration betweenGlaxoSmithKlineandLigand Pharmaceuticalsand is transferred to Novartis Pharmaceuticals. Eltrombopag was approved for medical use in the US in November 2008,and authorized in the European Union in March 2010.